Hamlet BioPharma
Invitation to digital meeting focusing on novel strategies for treating bacterial infections without antibiotics
As stated in the Davos Summit Program: "Antimicrobial resistance (AMR) is already undermining modern medicine. As superbugs evolve faster than new treatments can be developed, once-manageable infections are becoming harder to cure, threatening everything from surgery to cancer care. How can we ensure global access to life-saving antibiotics while preserving their effectiveness for generations to come?"
https://www.weforum.org/meetings/world-economic-forum-annual-meeting-2026/programme
Our discussions will focus on the groundbreaking ongoing development in Hamlet BioPharma's novel strategies for treating bacterial infections without antibiotics. Results from a successful clinical study were recently accepted for publication in Nature Microbiology, a leading international journal in the field of infection.
Link to the meeting: https://us06web.zoom.us/j/88631809029?pwd=Uy1FVnDW5B7mc3D5cA2NCA5Kquh1jm.1
For more information please contact:
Catharina Svanborg, Chair of the Board, Hamlet BioPharma, +46-709 42 65 49
catharina.svanborg@hamletpharma.com
Ines Ambite, Senior Scientist, Lund University, +46-762 08 89 58
| Datum | 2026-01-16, kl 14:00 |
| Källa | Cision |